← Latest edition
Edition ·

November 3, 2025


Uncommon Therapeutics

A disease-focused biotech building multiple billion-dollar drugs

Gene TherapyCRISPRBiotechnology

Uncommon Therapeutics Is a Father's Bet That Rare Disease Drugs Don't Have to Take 20 Years

Noah Auerhahn's daughter was diagnosed with Rett Syndrome, a condition affecting 1 in 10,000 girls. He invested over $1 million in research, assembled a team with deep neuroscience expertise, and is now building a polytherapy strategy that could change how rare diseases get treated.